Videos

“Doing this study allows us to say, 'With repeat treatments, we're not seeing a greater risk of retention, and we're not seeing a greater risk of UTI,'" says David A. Ginsberg, MD.

An expert in endourology discusses concerns with currently available treatment options for enteric hyperoxaluria and comments on detecting the disease for patients with recurring stones.

“The goal of this study was to look at that original phase 3 trial data [from 2013] and see if we could identify how much change in curvature patients were achieving with each of those 2 injections,” says Matthew J. Ziegelmann, MD.

“Most importantly, for the safety [of the] study…it looks like the medication has no really concerning adverse effects,” says Ronald Swerdloff, MD.

“I think that a lot of the best practices that the surgeons had developed and honed were really excellent communication skills, and…building a trusting physician-patient relationship, where they truly provided an informed consent of all the risks, all the benefits, [and] all the alternatives,” says Una Lee, MD, FPMRS.

Based on long-term data and clinical experience treating advanced prostate cancer with androgen receptor inhibitors, Drs Julie N. Graff and Benjamin H. Lowentritt suggest ideas for future study.

Considerations that factor into which androgen receptor inhibitor is selected as treatment for nonmetastatic castration-resistant prostate cancer.

“Most importantly, the improvement that they were able to get during the first couple of years is sustained, whereas what we expect in untreated men [is that] their erectile function…keeps on deteriorating,” says Karim Sultan Haider, MD.

“[Attendees] will be learning multiple aspects in terms of the genetic evaluation for men with prostate cancer,” says Veda N. Giri, MD.

Welcome to another installment of Uranimals, a video series featuring urologists and their pets, brought to you by urology times. From a snuggling cat companion to an Australian parakeet, we have some more great guests for you!

“I think the most exciting thing in the Sexual Medicine sphere is the stride for equity, diversity, and inclusion,” says Jesse N. Mills, MD.

Steven A. Kaplan, MD, gives an overview of benign prostatic hyperplasia research highlights from the 2021 American Urological Association Annual Meeting.

“This study suggests that the treatment of a patient's underlying hypogonadism or sexual dysfunction may be protective in the use of finasteride for alopecia or BPH,” says Kevin J. Campbell, MD, MS.

“The difference between this compound and other compounds that were orally administered, is that this seems to go through the lymphatic system rather than going directly to the liver,” says Ronald Swerdloff, MD.

“What we wanted to do was to substantiate any difference between BPH and alopecia with finasteride and also people who are concomitantly taking testosterone for hypogonadism,” says Kevin J. Campbell, MD, MS.

“There's 3 different levels of dosing…so this does provide you with a mechanism for titration if you're going to be using that in your patients,” says Jesse N. Mills, MD.

“The initial levels were inversely related to body mass index, so…men who are the largest…or had the largest BMI have the lowest testosterone levels,” says Martin M. Miner, MD.

Julie N. Graff, MD, highlights the efficacy associated with the use of androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer.

Judd W. Moul, MD discusses data on real-world effectiveness and treatment adherence of apalutamide in non-metastatic castration-resistant prostate cancer patients that was presented at the American Urological Association 2021 Annual Meeting.

Various factors that medical oncologists consider when selecting to treat metastatic castration-sensitive prostate cancer with either apalutamide or enzalutamide.

“I think this AUA was really exciting for anyone that treats OAB and incontinence because there were a number of really interesting studies,” says Ekene Enemchukwu, MD, MPH.

Nicole L. Miller, MD, FACS, discusses studies involving ultrasonic propulsion to facilitate clearance of fragments, dusting vs basketing, and more.

“The main advantages with regard to the Zenflow Spring System are that there's no piercing, there's no trauma, and there's no heat involved with the treatment,” says Peter Chin, MD.

“Bottom line, there's really no way to separate all of the things that we do, but I think we can all be more conscious on a day-to-day basis in terms of our own environmental footprint and just making better choices,” says Stacy Loeb, MD, PhD, MSc.

By identifying trends in race and ethnicity of academic urologists, this study poses as an opportunity for future intervention.

Alicia Morgans, MD, MPH, discusses a health economics analysis that assessed the clinical and cost impact of cabazitaxel (Jevtana) as a third-line treatment for patients with metastatic castration-resistant prostate cancer.

“This is an opportunity for [patients with NMIBC] to have a treatment that is successful and…promising in terms of its durability of responding to the treatment,” says William C. Huang, MD.

“What we found was [that] every subgroup, whether they were less than or greater than 100 mLs, or whether they had an obstructive median lobe or didn't have a median lobe, [all] showed significant improvements…regardless of their subcategory,” says Dean Elterman, MD, MSc, FRCSC.

Scott T. Tagawa, MD, discusses a study of treatment patterns and overall survival in metastatic castration-sensitive prostate cancer between 2006 and 2019.

Tian Zhang , MD, discusses the adaptive phase 3 PDIGREE study comparing immunotherapy only versus immunotherapy/TKI regimens in patients with advanced kidney cancer.